Yunqi Capital Ltd Purchases 252,113 Shares of STAAR Surgical (NASDAQ:STAA)

Yunqi Capital Ltd increased its holdings in STAAR Surgical (NASDAQ:STAA - Free Report) by 48.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 767,413 shares of the medical instruments supplier's stock after buying an additional 252,113 shares during the quarter. STAAR Surgical accounts for about 11.9% of Yunqi Capital Ltd's investment portfolio, making the stock its 3rd largest position. Yunqi Capital Ltd owned approximately 1.56% of STAAR Surgical worth $18,640,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Quarry LP purchased a new stake in STAAR Surgical during the 3rd quarter valued at approximately $50,000. Quest Partners LLC bought a new position in shares of STAAR Surgical in the third quarter worth about $128,000. Van ECK Associates Corp raised its position in STAAR Surgical by 12.7% during the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier's stock valued at $129,000 after purchasing an additional 393 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of STAAR Surgical by 78.3% in the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier's stock worth $181,000 after purchasing an additional 2,135 shares during the period. Finally, Creative Planning boosted its position in STAAR Surgical by 8.0% during the third quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier's stock valued at $205,000 after purchasing an additional 408 shares in the last quarter. 96.70% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. bought 23,000 shares of the company's stock in a transaction that occurred on Wednesday, December 18th. The shares were acquired at an average price of $24.33 per share, with a total value of $559,590.00. Following the completion of the transaction, the insider now owns 10,848,631 shares of the company's stock, valued at $263,947,192.23. The trade was a 0.21 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have purchased 910,843 shares of company stock worth $15,509,972. 1.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

STAA has been the subject of a number of research analyst reports. Piper Sandler reduced their target price on STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating for the company in a research note on Wednesday, February 12th. Canaccord Genuity Group reduced their price target on shares of STAAR Surgical from $28.00 to $17.00 and set a "hold" rating for the company in a research report on Thursday, February 13th. Jefferies Financial Group cut STAAR Surgical from a "buy" rating to a "hold" rating in a report on Wednesday, February 12th. Mizuho cut STAAR Surgical from an "outperform" rating to a "neutral" rating and lowered their price target for the stock from $45.00 to $17.00 in a report on Wednesday, February 12th. Finally, Needham & Company LLC reissued a "hold" rating on shares of STAAR Surgical in a research report on Thursday, February 27th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, STAAR Surgical currently has a consensus rating of "Hold" and an average target price of $26.86.

STAAR Surgical Trading Down 1.9 %

NASDAQ STAA traded down $0.34 during trading hours on Wednesday, reaching $18.00. 719,795 shares of the company traded hands, compared to its average volume of 1,123,937. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $52.68. The company has a 50 day moving average of $20.81 and a two-hundred day moving average of $26.44. The stock has a market capitalization of $887.85 million, a PE ratio of -43.90 and a beta of 0.66.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.